Key Takeaways from AACR 2023, AACR 2023

Key Takeaways from AACR Annual Meeting 2023

Cromos Pharma’s Chief Operating Officer, Stephanie Finnegan, recently attended the AACR Annual Meeting, on April 14-19 in Orlando, FL. She took part in discussions with key opinion leaders about current preclinical and clinical research trends and held a significant number of meetings with Sponsors to discuss their development program plans and challenges. Stephanie’s key takeaways from this year’s AACR:

  • The fight against cancer requires a collaborative effort across many different disciplines and organizations. The AACR conference emphasized the importance of collaboration and featured several presentations on innovative partnerships and initiatives to accelerate progress in cancer research.
  • Immunotherapy has emerged as a powerful tool in the fight against cancer, and the AACR conference highlighted several breakthrough studies on this approach.
  • One of the key topics was “Personalized cancer vaccines.” Conference attendees were presented with, among other topics, impactful results of pancreatic cancer and melanoma vaccine studies.
  • Research professionals are becoming more aligned in several areas:  Sharing of metadata, collaborating with CDMOs, CMOs, CROs, and preclinical experts to develop more streamlined, cost effective and meaningful development plans.

The AACR Annual Meeting serves as the hub of the cancer research community. For Сromos Pharma, an annual visit to AACR has become a tradition. The meeting consistently provides excellent opportunities for attendees to network with peers, share best practices, and learn from industry experts. 

Look for us at AACR in San Diego, CA, on April 5-10, 2024. We hope to see our loyal clients and our new potential partners!

If you have any questions or want to find out more about how Cromos Pharma can support your next clinical trial please contact us by emailing



To arrange an introductory meeting and find out how our experience can benefit your next clinical project.